A. Menarini Pharmaceuticals Ireland has updated the appearance of Brimica Genuair (aclidinium bromide/ formoterol fumarate dihydrate). Brimica Genuair is an approved anticholinergic and selective long-acting b2-agonist combination for treating symptoms in adults with chronic obstructive pulmonary disease. The changes are limited to the device and packaging only. The colour of the cap and dosage button of the inhaler will change from turquoise to orange. The changeover will be introduced this month and is estimated to be completed by the end of June. Short acting beta-agonists are commonly referred to as “blue inhalers” and while there has not been any issue related to the turquoise colour since the launch of Brimica Genuair in Ireland, the decision has been made to pro-actively change the colour of the cap and dosage button to ensure that COPD patients do not associate Brimica Genuair with short acting/reliever medication.
Further information is available at A. Menarini Pharmaceuticals medical information on 01 2846744.